| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS46000468 | BKPyv | ENSG00000100385.15 | protein_coding | IL2RB | No | No | 3560 | P14784 |
| TVIS30001116 | HIV | ENSG00000100385.15 | protein_coding | IL2RB | No | No | 3560 | P14784 |
| TVIS30016067 | HIV | ENSG00000100385.15 | protein_coding | IL2RB | No | No | 3560 | P14784 |
| TVIS30004832 | HIV | ENSG00000100385.15 | protein_coding | IL2RB | No | No | 3560 | P14784 |
| TVIS30014260 | HIV | ENSG00000100385.15 | protein_coding | IL2RB | No | No | 3560 | P14784 |
| TVIS30008161 | HIV | ENSG00000100385.15 | protein_coding | IL2RB | No | No | 3560 | P14784 |
| TVIS30017257 | HIV | ENSG00000100385.15 | protein_coding | IL2RB | No | No | 3560 | P14784 |
| TVIS30016998 | HIV | ENSG00000100385.15 | protein_coding | IL2RB | No | No | 3560 | P14784 |
| TVIS30019395 | HIV | ENSG00000100385.15 | protein_coding | IL2RB | No | No | 3560 | P14784 |
| TVIS30019405 | HIV | ENSG00000100385.15 | protein_coding | IL2RB | No | No | 3560 | P14784 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | IL2RB |
|---|---|
| DrugBank ID | DB00074 |
| Drug Name | Basiliximab |
| Target ID | BE0000651 |
| UniProt ID | P14784 |
| Regulation Type | antibody |
| PubMed IDs | 10188761; 10708100; 11840795; 12667677; 12826150; 11752352 |
| Citations | Onrust SV, Wiseman LR: Basiliximab. Drugs. 1999 Feb;57(2):207-13; discussion 214.@@Hausen B, Gummert J, Berry GJ, Christians U, Serkova N, Ikonen T, Hook L, Legay F, Schuler W, Schreier MH, Morris RE: Prevention of acute allograft rejection in nonhuman primate lung transplant recipients: induction with chimeric anti-interleukin-2 receptor monoclonal antibody improves the tolerability and potentiates the immunosuppressive activity of a regimen using low doses of both microemulsion cyclosporine and 40-O-(2-hydroxyethyl)-rapamycin. Transplantation. 2000 Feb 27;69(4):488-96.@@Schmitz K, Hitzer S, Behrens-Baumann W: [Immune suppression by combination therapy with basiliximab and cyclosporin in high risk keratoplasty. A pilot study]. Ophthalmologe. 2002 Jan;99(1):38-45.@@Warle MC, Kwekkeboom J, Tilanus HW, Metselaar HJ: Basiliximab interferes with the detection of soluble IL-2 receptor by the Immulite Immunoassay system. J Immunol Methods. 2003 Apr 1;275(1-2):133-6.@@Emparan C, Laukotter M, Wolters H, Dame C, Heidenreich S, Senninger N: Calcineurin-free protocols with basiliximab induction allow patients included in "old to old" programs achieve standard kidney transplant function. Transplant Proc. 2003 Jun;35(4):1326-7.@@Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. |
| Groups | Approved; Investigational |
| Direct Classification | Peptides |
| SMILES | |
| Pathways | |
| PharmGKB | PA164747126 |
| ChEMBL | CHEMBL1201439 |
